Currently, valid diagnostic tools for AD include both CSF biomarkers (Aβ42 and Tau) and imaging methods (MRI and PET) for the study of brain atrophy and metabolism or accumulation of pathogenic substances [12]. This evidence concerns the gene MAPT and Alzheimer disease.